Principal Investigator: Kelly Brant (CTP Contact: Gladys Erives)
Funding Mechanism: Research Contract
ID Number: HHSF22320151001I
Award Date: 8/27/2015
Institution: Lovelace Biomedical and Environmental Research Institute (LBERI)
More information about the toxicity differences between cigarette smoke and e-cigarette aerosol would be useful. The goals of this study are to compare the in vitro mutagenicity, cytotoxicity, and genotoxicity of total particulate matter (TPM) generated from conventional cigarettes to that of e-cigarettes, and to characterize the qualitative and quantitative profiles of conventional cigarette smoke and e-cigarette aerosols. Researchers will select 15 cigarettes of different brands and six e-cigarettes representative of first, second and third generation devices based on market share. Researchers will generate TPM from conventional cigarettes using the Canadian Intense (CI) and the International Organization for Standardization (ISO) regimens, and generate TPM from e-cigarettes using a modified puffing protocol described by Behar et al. (PLoS One 2015;10(2):e0117222). They will then quantify nicotine in TPM from each of the samples collected and measure nicotine and cotinine levels using the gas chromatography-mass spectrometry (GC-MS) method. Cytotoxicity will be assessed using the Neutral Red Uptake assay; genotoxicity will be assessed using the micronucleus assay; and mutagenic potency will be assessed using the bacterial Ames test and the thymidine kinase gene mutation assay. Study findings will provide new information about the differences in toxicity profiles between cigarette smoke and e-cigarette aerosol.